AMRN — Amarin Corporation plc
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: IE
- Exchange: NASDAQ
- Employees: 275
- Website: https://www.amarincorp.com
Latest SEC filings for AMRN
- 8-K — 2026-05-15
- 10-Q — 2026-04-29
- 8-K — 2026-04-29
- ARS — 2026-04-10
- 8-K — 2026-03-27
- 10-K — 2026-03-02
- 8-K — 2026-02-25
- 8-K — 2026-01-08
Latest AMRN news
- — FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer (Zacks Investment Research)
- — Here's Why You Should Add EYPT Stock to Your Portfolio Now (Zacks Investment Research)
- — RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week (Zacks Investment Research)
- — LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label (Zacks Investment Research)
- — Here's Why You Should Add ANRO Stock to Your Portfolio Now (Zacks Investment Research)
- — Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal (Zacks Investment Research)
- — BMY Reports Mixed Phase III Trial Results, Stock Down (Zacks Investment Research)
- — Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why (Zacks Investment Research)
- — PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know (Zacks Investment Research)
- — argenx Meets Primary Endpoint in Phase II Celiac Disease Study (Zacks Investment Research)
Educational tool only — not investment advice.